TD Cowen analyst Tyler Van Buren raised the firm’s price target on Crispr Therapeutics (CRSP) to $45 from $40 and keeps a Hold rating on the shares. The firm said Casgevy momentum is building with FY 2025 sales of $116MM and a line of sight into $200MM+ for 2026. Most exciting is the numerous clinical updates the company will share in H2.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- CRISPR Therapeutics: Casgevy Outperformance and Advancing In Vivo Pipeline Underpin Buy Rating
- Crispr Therapeutics price target lowered to $86 from $89 at BofA
- CRISPR Therapeutics: Buy-Rated, Multi-Franchise Gene-Editing Platform with Strengthening CASGEVY Launch and Catalyst-Rich 2026 Outlook
- Maintaining a Hold: Casgevy Outperformance Balanced by Pipeline Execution Risks and Limited Valuation Upside
- Crispr Therapeutics: Buy Rating on Strengthening Casgevy Trajectory and High-Value In Vivo Gene-Editing Pipeline